# Efficacy and Safety of LP-003 Injection in Patients With Moderate to Severe Seasonal Allergic Rhinitis

> **NCT07291284** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Longbio Pharma** · enrollment: 546 (actual)

## Conditions studied

- Seasonal Allergic Rhinitis

## Interventions

- **BIOLOGICAL:** LP-003
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT07291284
- **Lead sponsor:** Longbio Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-08-01
- **Primary completion:** 2026-03-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 546 (ACTUAL)
- **Last updated:** 2025-12-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07291284

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07291284, "Efficacy and Safety of LP-003 Injection in Patients With Moderate to Severe Seasonal Allergic Rhinitis". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07291284. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*